• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment†

  1. Patrick R. Harrington1,‡,*,
  2. Wen Zeng2,
  3. Lisa K. Naeger1,‡,*

Article first published online: 1 MAR 2012

DOI: 10.1002/hep.24791

Issue

Hepatology

Hepatology

Volume 55, Issue 4, pages 1048–1057, April 2012

Additional Information

How to Cite

Harrington, P. R., Zeng, W. and Naeger, L. K. (2012), Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology, 55: 1048–1057. doi: 10.1002/hep.24791

Author Information

  1. 1

    Division of Antiviral Products, Office of Antimicrobial ProductsCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

  2. 2

    Division of Biometrics IV, Office of Biometrics, Office of Translational Sciences; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

  1. ‡

    fax: 301-796-9883

*FDA/CDER/OAP/DAVP, 10903 New Hampshire Ave., Silver Spring, MD 20993

  1. †

    Potential conflict of interest: Nothing to report.

  2. ‡

    fax: 301-796-9883

Publication History

  1. Issue published online: 27 MAR 2012
  2. Article first published online: 1 MAR 2012
  3. Accepted manuscript online: 16 NOV 2011 07:44AM EST
  4. Manuscript Accepted: 24 OCT 2011
  5. Manuscript Received: 7 SEP 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1225K)

References

  • 1
    Perlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889–900.
  • 2
    U.S. Food and Drug Administration. Chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Draft Guidance for Industry; September 2010.
  • 3
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954–960.
    Direct Link:
  • 4
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451–458.
  • 5
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335–1374.
    Direct Link:
  • 6
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.
  • 7
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217.
  • 8
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011; 364: 2417–2428.
  • 9
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011; 364: 2405–2416.
  • 10
    U.S. Food and Drug Administration. Antiviral Drug Advisory Committee Meeting and Briefing Materials for Boceprevir, April 27, 2011.
  • 11
    U.S. Food and Drug Administration. Antiviral Drug Advisory Committee Meeting and Briefing Materials for Telaprevir, April 28, 2011.
  • 12
    Victrelis (boceprevir) Capsules. US Prescribing Information. Whitehouse Station, NJ: Merck; May 2011.
  • 13
    Incivek (telaprevir) Film Coated Tablets. US Prescribing Information. Cambridge, MA: Vertex Pharmaceuticals; May 2011.
  • 14
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–716.
  • 15
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827–1838.
  • 16
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839–1850.
  • 17
    COBAS TaqMan HCV Test, v2.0, For Use With The High Pure System (Doc Rev. 1.0). U.S. Package Insert. Branchburg, NJ: Roche Molecular Systems; September 2010.
  • 18
    Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011; 140: 676–685.
  • 19
    Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821–829.
  • 20
    Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453–463.
View Full Article (HTML) Get PDF (1225K)